GLP-1-CHI

Unknown

GLP-1 Receptor Expression in CHI

The Physiology of Glucagon-like-peptide-1 Espression in Patients With Endogenous Hyperinsulinism: Correlation With Histopathology

Lead sponsor

Radboud University Medical Center

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Prediabetes / glucose intolerance

Eligibility highlights

•Age ≤16

Primary endpoint

•Expression and distribution of GLP-1R in pancreas of children with CHI

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03768518

Org study IDNL54275.091.15

Timeline

Milestones

Study start2018-02-07actual

Study first posted2018-12-07actual

Last update posted2018-12-07actual

Primary completion2019-02-01estimated

Study completion2019-02-01estimated

Assets

Investigational agents

Exenatide

Who this study enrolls

Prediabetes / glucose intolerance

Who can enroll

Maximum age16 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

patients (\<16 years) with biochemically proven endogenous congenital hyperinsulinism

Inclusion criteria

•Biochemically and clinically proven endogenous congenital hyperinsulinism:

•Unresponsive to medical treatment (diazoxide)

•Indication for 18F-DOPA PET/CT based on mutation analysis

•Standard imaging (18F-DOPA PET/CT) not older than 8 weeks

•<16 years old

•Informed consent signed by parents or legal guardians of the patient.

Exclusion criteria

•Genetically proven diffuse CHI (presenting with a homozygous or compound heterozygous ABCC8/KCNJ11 mutation)

•Calculated creatinine clearance below 40 ml/min

•Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions based on CT)

•Age > 16 years

•No signed informed consent

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Other (unclassified)

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Comparison of the exendin PET/CT and F-DOPA PET/CT

Time frame:1 year

descriptive

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Expression and distribution of GLP-1R in pancreas of children with CHI

Time frame:1 year

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.